Updated Outcome and Treatment Benefit Data from MINDACT Study Reinforce Real-World Value of MammaPrint ® for Clinical Low Risk Breast Cancer Patients at SABCS 2020
Agendia, Inc., a world leader in precision oncology for breast cancer, today announced that additional data from its groundbreaking MINDACT study will be highlighted in an oral presentation by Laura van ’t Veer, Ph.D., Co-founder and Chief Research Officer, at the 2020 San Antonio Breast Cancer Symposium (SABCS 2020). These data highlight the ability of MammaPrint®, Agendia’s 70-gene breast cancer recurrence assay, to further stratify patients with clinically low risk breast cancer which could impact physician-patient discussions and treatment planning.
MINDACT (Microarray In Node-Negative and 1-3 node-positive Disease may Avoid ChemoTherapy), the Phase 3, prospective, randomized clinical trial supported by the European Organization for Research and Treatment of Cancer (EORTC), was designed to determine whether MammaPrint could be used to safely de-escalate patients with early stage breast cancer from chemotherapy without compromising their outcomes. Updated outcome and treatment data from the trial shared at SABCS 2020 build upon nearly 9-year follow-up results debuted at ASCO 2020 and confirm MINDACT as a positive de-escalation study.
Dr. van ’t Veer’s presentation showed that the combination of clinical low risk and MammaPrint Low Risk results indicate excellent 8-year prognosis – these patients showed a distant metastasis-free survival rate of 94.7% with no chemotherapy. Of note, amongst the clinically low risk study population, distant metastasis free survival at 8 years was 3.6% better in MammaPrint Low Risk patients as compared to those with a High Risk result.
“Collectively, these data produce a significant library of evidence that will allow for the precise treatment of breast cancer, including insights into a patient population considered low risk,” said Dr. van ’t Veer. “Within this population, further stratification by genomic signature into MammaPrint Low or High Risk should be weighed for further treatment planning.”
These data are part of a large suite of 13 posters, spotlight sessions and an oral presentation on MammaPrint and BluePrint that were accepted to SABCS 2020, and underscore Agendia’s mission to help guide the diagnosis and personalized treatment of breast cancer for all patients throughout their treatment journey.
About Agendia
Agendia is a precision oncology company headquartered in Irvine, California, committed to bringing early stage breast cancer patients and their physicians the information they need to make the best decisions for the full treatment journey. The company currently offers two commercially-available genomic profiling tests, supported by the highest levels of clinical and real world evidence, that provide comprehensive genomic information that can be used to identify the most effective breast cancer treatment possible for each patient.
MammaPrint®, the 70-gene breast cancer recurrence assay, is the only FDA-cleared risk of recurrence test backed by peer-reviewed, prospective outcome data and inclusion in both national and international treatment guidelines. BluePrint®, the 80-gene molecular subtyping assay, is the only commercially-available test that evaluates the underlying biology of a tumor to determine what is driving its growth. Together, MammaPrint® and BluePrint® provide a comprehensive genomic profile to help physicians make more informed decisions in the pre- and post-operative treatment settings.
Agendia develops evidence-based novel genomic tests and forges partnerships with groundbreaking companies to develop next-generation digital treatment tools. The ongoing research builds an arsenal of data that improve patient outcomes and support the evolving clinical needs of breast cancer patients and their physicians every step of the way, from initial diagnosis to cancer-free.
Agendia’s assays can be ordered on core biopsies or surgical specimens to inform pre- and post-operative treatment decisions. For more information on Agendia’s assays and ongoing trials, please visit www.agendia.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201211005005/en/
Contact information
Terri Clevenger
Westwicke/ICR Healthcare PR
Tel: 203.856.4326
Terri.Clevenger@icrinc.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Global Enters Malawi19.1.2021 15:30:00 CET | Press release
Andersen Global establishes a foothold in the Malawi market through a Collaboration Agreement with Knight & Knight, bolstering its platform on the African continent and adding additional coverage in the eastern region. Established in 2003, Knight & Knight is a full-service law firm specializing in all facets of business law with capabilities in banking and finance, litigation, intellectual property, commercial, real estate, employment, mergers and acquisitions, and regulatory matters. With two partners and six professionals, the firm serves individuals and organizations of various sizes, representing a large number of businesses across the country as well as transactional entities, multinational corporations, banking and financial institutions, public sector undertakings, various ministries, state and central government authorities, and nongovernmental organizations. “At the core of our business, our philosophy has always been to offer best-in-class services designed to meet our client
Pitney Bowes Appoints Ana Maria Chadwick as Executive Vice President and Chief Financial Officer19.1.2021 15:00:00 CET | Press release
Pitney Bowes (NYSE: PBI), a global technology company that provides commerce solutions in the areas of ecommerce, shipping, mailing and financial services, today announced that Ana Maria Chadwick has been appointed Executive Vice President and Chief Financial Officer, effective January 29, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005596/en/ Pitney Bowes Appoints Ana Chadwick as Executive Vice President and CFO (Photo: Business Wire) Ms. Chadwick joins Pitney Bowes from GE Capital where she held several executive positions. Her responsibilities included both operational and financial positions, along with strong transformational and financial services experience. Most recently, Ms. Chadwick was President and CEO of GE Capital Global Legacy Solutions. Previously, she was Controller of GE Capital Americas and Chief Financial Officer at GE Capital Energy Financial Services. Ms. Chadwick also has substantial glo
Globality, the World’s First Smart Sourcing Platform Powered by AI, Raises $138.3 Million of Series E Funding From Sienna Capital, a Wholly Owned Subsidiary of Groupe Bruxelles Lambert, and the SoftBank Vision Fund19.1.2021 14:00:00 CET | Press release
Globality, the leading AI-powered digital solution for sourcing strategic services, announced today it has closed an investment of $138.3 million from Sienna Capital, a wholly owned subsidiary of Groupe Bruxelles Lambert (GBL), and the SoftBank Vision Fund. This new investment brings Globality’s total funding to $310.3 million since being founded five years ago. As part of the investment, Colin Hall, vice-chairman of Sienna Capital, will join the company’s board of directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005308/en/ Joel Hyatt, Co-Founder, Chairman, and CEO of Globality (Photo: Business Wire) The Series E round of funding enables Globality to fuel its rapid growth by investing in additional AI technology capabilities. It also directly supports the company’s efforts to increase its global scale and capacity; add world-class talent to the engineering, product and client teams; and expand its marketing an
Zynga Launches Harry Potter: Puzzles & Spells in South Korea19.1.2021 14:00:00 CET | Press release
Zynga Inc. (Nasdaq: ZNGA): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005175/en/ Zynga Launches Harry Potter: Puzzles & Spells in South Korea (Graphic: Business Wire) WHO: Zynga Inc. (Nasdaq: ZNGA), a global leader in interactive entertainment, announced that Harry Potter: Puzzles & Spells has launched in South Korea. Officially licensed from Warner Bros. Games and published under the Portkey Games label, this award-winning mobile game has begun rolling out to players in South Korea, fully localized in Korean. WHAT: Recipient of a Google Play 2020 Award for Best Casual Game and Apple App Store Editors’ Choice Award, Harry Potter: Puzzles & Spells is now available for free download on the App Store and Google Play in South Korea. Players in this region can access all current and previously released content, featuring more than 1,000 magic-infused Match-3 puzzles inspired by the story of Harry Potter and the wizardin
PPRO Raises $180 Million for the Next Era of Local Payments Infrastructure, Is Now Valued Over $1 Billion19.1.2021 14:00:00 CET | Press release
PPRO, the global provider of local payments infrastructure, today announced over US $180 million in new investment. Investors include Eurazeo Growth, Sprints Capital, and Wellington Management. This news comes just six months after the company raised US $50 million from Sprints Capital as well as Citi Ventures and HPE Growth. PPRO’s valuation is now over US $1 billion. PPRO has established itself as the most trusted infrastructure provider in the cross-border payments space, powering international growth for payment service providers and platforms such as Citi, Elavon, Mastercard Payment Gateway Services, Mollie, PayPal, and Worldpay. PPRO’s local payments platform and expert services help its customers get the industry’s best conversion rates in markets around the world by allowing online shoppers to pay with their preferred payment method. PPRO’s valuation is underscored by its rapid growth last year. The company doubled its year-on-year transaction volumes in the fourth quarter of 2
ARTMS and Isotopia Molecular Imaging Announce Successful Multi-Curie Labeling of PSMA-11 With Cyclotron Produced 68 Ga Utilizing the QUANTM Irradiation System™ and Solid Targets19.1.2021 14:00:00 CET | Press release
ARTMS Inc. (ARTMS) and Isotopia MolecularImaging (Isotopia) are pleased to announce the successful radiolabeling of Isotopia’s prostate cancer imaging kit product, PSMA-11, with over 2 Ci of cyclotron-produced Gallium-68 (68Ga) using ARTMS’ proprietary Quantum Irradiation System™ (QIS™) solid target system. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005044/en/ The specially designed Prostate-Specific Membrane Antigen (PSMA) kit for the preparation of 68Ga-PSMA-11 (a radiopharmaceutical targeting PSMA for the imaging of prostate cancer using Positron Emission Tomography (PET)) was radiolabeled with high activity cyclotron produced 68Ga following irradiation times of less than two hours. The Isotopia kit was radiolabeled with between 500 mCi and just over 2900 mCi of 68Ga following multiple successful 68Ga production runs utilizing the QIS™ and ARTMS’ high performance 68Zn solid targets. The resultant product demonst
Everbridge Unveils Next-Generation Front-End Alerting Interface for Industry-Leading Global Public Warning Platform19.1.2021 13:30:00 CET | Press release
Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced the launch of its enhanced Public Warning Center, the first-of-its-kind modular and multi-channel front-end interface featuring the ability to create and transmit a combination of cell broadcast and address-, group-, and location-based SMS alerts for countrywide alerting from a single console. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210119005380/en/ Critical Event Management (CEM) leader announces new Public Warning Center (Photo: Business Wire) Offering a best-in-class user interface (UI) and modern design, the highly-flexible Public Warning Center serves as the gateway for the industry’s largest and only public warning system supporting any configuration from basic single-channel to more sophisticated hybrid options combining cell-broadcast and multi-channel technologies, including SMS, video, social media, TV, rad